Artiva Biotherapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 29, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 29, 2024
ARTV$4.22+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Item 6. | Exhibits. |
|---|
| Exhibit number · Description of document · Incorporated by Reference · FiledHerewith | |||||
|---|---|---|---|---|---|
| Form · Date · Number | |||||
| 3.1 | Amended and Restated Certificate of Incorporation. | 8-K | 7/22/2024 | 3.1 | |
| 3.2 | Amended and Restated Bylaws. | S-1 | 6/28/2024 | 3.4 | |
| 4.1 | Form of Common Stock Certificate of the Registrant. | S-1/A | 7/15/2024 | 4.1 | |
| 4.2 | Amended and Restated Investors’ Rights Agreement, dated February 22, 2021, by and among the Registrant and certain of its stockholders. | S-1 | 6/28/2024 | 4.2 | |
| 10.1+ | Form of Indemnity Agreement, by and between the Registrant and its directors and officers. | S-1 | 6/28/2024 | 10.1 | |
| 10.2+ | The Registrant’s 2024 Equity Incentive Plan | S-8 | 7/22/2024 | 99.3 | |
| 10.3+ | Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the Registrant’s 2024 Equity Incentive Plan. | S-1/A | 7/15/2024 | 10.5 | |
| 10.4+ | Forms of Restricted Stock Unit Grant Notice and Award Agreement under the Registrant’s 2024 Equity Incentive Plan. | S-1/A | 7/15/2024 | 10.6 | |
| 10.5+ | The Registrant’s 2024 Employee Stock Purchase Plan. | S-8 | 7/22/2024 | 99.6 | |
| 10.6+ | The Registrant’s Non-Employee Director Compensation Policy. | S-1/A | 7/15/2024 | 10.8 | |
| 10.7+ | Employment Offer Letter, dated April 15, 2024, by and between the Registrant and Neha Krishnamohan. | S-1 | 6/28/2024 | 10.36 | |
| 10.8+ | Consulting Agreement dated November 1, 2023, as amended, by and between the Registrant and Diego Miralles, M.D. | S-1 | 6/28/2024 | 10.38 | |
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1* | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 101.INS | Inline XBRL Instance Document | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With embedded Linkbase Documents Document | X | |||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | X | |||
| + | Indicates management contract or compensatory plan |
|---|
| * | This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.